Novotech Raises $255 Million to Expand Asia-China Clinical CRO Operations

Novotech Health Holdings Pte, a clinical CRO with integrated labs and Phase I facilities, completed a $255 million financing. Novotech is an Asia-Pacific CRO that consists of Novotech in Singapore and Australia and PPC in mainland  China . The two companies merged in 2020. Novotech said it would use the funds to pursue M&A that will expand its geographical footprint while also adding data, AI and tech-enabled services. The financing valued Novotech at $3 billion. Novotech offers clinical CRO services for all indications and all clinical trial phases. More details.... Share this with colleagues: // //